开发一种新的算法来识别医疗保险索赔中的事件和流行痴呆症. 在ARIC研究的研究
Tiansheng Wang1, Virginia Pate1, Dae Hyun Kim2
1Department of Epidemiology, University of North Carolina at Chapel Hill, Gillings School of Global Public Health.
American journal of epidemiology
|August 4, 2025
概括
使用Medicare索赔开发强大的痴呆症识别算法对于药物效应研究至关重要. 我们的新算法表现出与现有方法相当的性能,影响了药物流行病学研究.
科学领域:
- 药学流行病学 药学流行病学
- 老年医学 老年医学
- 医疗信息学 医疗信息学
背景情况:
- 准确的痴呆症确定对于现实世界的药物安全性和疗效研究至关重要.
- 现有的痴呆症识别算法在大型医疗保健数据集中可能缺乏稳定性.
- 社区动脉样硬化风险研究 (ARIC) 为验证提供了有价值的队列.
研究的目的:
- 利用医疗保险索赔数据开发和验证新的痴呆症识别算法.
- 将新开发的算法与现有的算法 (Jain,Bynum,Lee) 的性能进行比较.
- 评估算法选择对估计药物对痴呆风险影响的影响.
主要方法:
- 开发了使用Medicare住院,门诊和处方索赔的事件和流行痴呆症算法.
- 对ARIC研究的综合性痴呆症分类进行验证的算法.
- 在一个医疗保险样本中评估了算法有效性,评估了对痴呆风险的liraglutide与二二酶4抑制剂 (DPP4i).
主要成果:
- 事件痴呆算法实现了69.2%的正预测值 (PPV) 和99.0%的特异性.
- 性能与现有算法相当,PPVs在58.7%至68.6%之间.
- 算法选择显著影响了liraglutide和DPP4i之间的痴呆症估计的3年调整风险差异 (aRD).
结论:
- 使用医疗保险索赔的新型痴呆症识别算法展示了强大的性能.
- 算法选择对药物流行病学研究中的治疗效果估计产生了重大影响.
- 改进的痴呆症确定方法对于可靠的现实世界药物评估至关重要.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262